Opinion|Videos|July 8, 2024
Outcomes from NATALEE and MonarchE
Dr. Dempsey discusses key results from the NATALEE and MonarchE trials.
Advertisement
Video content above is prompted by the following:
- (Dr. O’Shaughnessy) How have the MonarchE and NATALEE trials contribute to our understanding of the optimal duration of adjuvant endocrine therapy?
- How might the difference in adjuvant therapy duration between ribociclib and abemaciclib influence discussions around risk-benefit assessments with patients considering CDK4/6i?
- (Dr. Rugo)How does incorporating CDK4/6i earlier in treatment impact how the relapsed/refractory setting is managed?
- Please include a discussion of ribociclib’s MAINTAIN trial. Discuss your thoughts on continued use of CDK4/6i in the R/R setting, as well as sequencing considerations.
- Please also include a discussion of capivasertib as a newly approved option based on the CAPItello-291 trial.
Advertisement
Related to this article
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Leukemia survivors given high-risk ALL therapy had hip bone density about 90% of matched controls, without the partial normalization seen in other groups.
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Sacral neuromodulation is still considered the gold standard for refractory overactive bladder, with tibial nerve stimulation a less invasive option.
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
The Omaha-based practice will hand its inbound faxes and document management to artificial intelligence (AI) agents, with outside records retrieval to follow.
Advertisement
Advertisement
Trending on AJMC
1
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
2
5 Things to Know if Retatrutide Is Classified as a Biologic
3
Sacral Neuromodulation Still Seen as OAB Gold Standard in Review
4
FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer
5